ZA200704924B - Methods for expression and purification of recombinant human growth hormone - Google Patents

Methods for expression and purification of recombinant human growth hormone

Info

Publication number
ZA200704924B
ZA200704924B ZA200704924A ZA200704924A ZA200704924B ZA 200704924 B ZA200704924 B ZA 200704924B ZA 200704924 A ZA200704924 A ZA 200704924A ZA 200704924 A ZA200704924 A ZA 200704924A ZA 200704924 B ZA200704924 B ZA 200704924B
Authority
ZA
South Africa
Prior art keywords
purification
expression
methods
growth hormone
recombinant human
Prior art date
Application number
ZA200704924A
Inventor
Buechler Ying
Lieu Ricky
Ong Michael
Bussell Stuart
Knudsen Nic
Cho Ho Sung
Original Assignee
Ambrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ambrx Inc filed Critical Ambrx Inc
Publication of ZA200704924B publication Critical patent/ZA200704924B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH] (Somatotropin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormones [GH] (Somatotropin)
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
    • C08G65/33396—Polymers modified by chemical after-treatment with organic compounds containing nitrogen having oxygen in addition to nitrogen
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875—Nucleoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
ZA200704924A 2004-12-22 2005-12-21 Methods for expression and purification of recombinant human growth hormone ZA200704924B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US63861604P 2004-12-22 2004-12-22

Publications (1)

Publication Number Publication Date
ZA200704924B true ZA200704924B (en) 2009-04-29

Family

ID=38943761

Family Applications (3)

Application Number Title Priority Date Filing Date
ZA200704926A ZA200704926B (en) 2004-12-22 2005-12-21 Modified human growth hormone
ZA200704924A ZA200704924B (en) 2004-12-22 2005-12-21 Methods for expression and purification of recombinant human growth hormone
ZA200704928A ZA200704928B (en) 2004-12-22 2005-12-21 Formulations of human growth hormone comprising a non-naturally encoded amino acid

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ZA200704926A ZA200704926B (en) 2004-12-22 2005-12-21 Modified human growth hormone

Family Applications After (1)

Application Number Title Priority Date Filing Date
ZA200704928A ZA200704928B (en) 2004-12-22 2005-12-21 Formulations of human growth hormone comprising a non-naturally encoded amino acid

Country Status (2)

Country Link
CN (3) CN101356269A (en)
ZA (3) ZA200704926B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012006980A (en) * 2009-12-21 2012-07-17 Ambrx Inc Modified porcine somatotropin polypeptides and their uses.
CN102062776A (en) * 2010-12-16 2011-05-18 中华人民共和国天津出入境检验检疫局 Babesia caballi disease immunoblotting detection method and preparation of kit
CN102838671B (en) * 2011-06-23 2014-06-11 北京大学 Growth hormone with site-specific mutagenesis and site-specific decoration, preparation method and applications of growth hormone
US20150038678A1 (en) * 2012-02-29 2015-02-05 Ambrx, Inc. Interleukin-10 Polypeptide Conjugates and Their Uses
GB201303876D0 (en) * 2013-01-29 2013-04-17 Verenium Corp Animal feed enzyme extraction
AU2019337610A1 (en) * 2018-09-11 2021-05-06 Ambrx, Inc. Interleukin-2 polypeptide conjugates and their uses
WO2023004686A1 (en) * 2021-07-29 2023-02-02 浙江新码生物医药有限公司 Unnatural amino acid, and use thereof, recombinant protein containing same, and recombinant protein conjugate
CN113698468B (en) * 2021-09-01 2022-10-11 浙江新码生物医药有限公司 Human interleukin 2-polyethylene glycol conjugate and application thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020077461A1 (en) * 1996-04-24 2002-06-20 Soren Bjorn Pharmaceutical formulation
AU2005209926B2 (en) * 2004-02-02 2007-09-06 Ambrx, Inc. Modified human four helical bundle polypeptides and their uses

Also Published As

Publication number Publication date
CN101374536A (en) 2009-02-25
CN101356269A (en) 2009-01-28
CN101374536B (en) 2013-09-25
CN101090980A (en) 2007-12-19
ZA200704928B (en) 2009-04-29
ZA200704926B (en) 2008-12-31

Similar Documents

Publication Publication Date Title
GB0713654D0 (en) Methods for expression and purification of recombinant human growth hormone
EP1901763A4 (en) Thyrotropin-releasing hormone analogs and method of use
HK1109062A1 (en) Compositions and methods of use for treatment of mammalian diseases
ZA200704924B (en) Methods for expression and purification of recombinant human growth hormone
EP1804746A4 (en) Airway implant and methods of making and using
IL182188A0 (en) Method and system for controlled thermal treatment of human superfical tissue
IL177849A0 (en) Methods and compositions for treatment of autoimmune diseases
AU2003257937A8 (en) Methods and compositions for treatment of dermal conditions
EP1838331A4 (en) Antimicrobial peptides and methods of use
EP1789109A4 (en) Dialysis implant and methods of use
GB0404345D0 (en) Surgical jig and methods of use
WO2005072055A9 (en) Novel brain natriuretic peptide variants and methods of use thereof
EP1691723A4 (en) Highly convertible endolumenal prostheses and methods of manufacture
EP1740103A4 (en) Apparatus and methods for securing tissue to bone
EP1758511A4 (en) Occipital fixation system and method of use
EP1804813A4 (en) Formulations and methods for treatment of inflammatory diseases
EP1581251A4 (en) Human growth hormone crystals and methods for preparing them
EP1746994A4 (en) Thienopyridinone compounds and methods of treatment
AU2003268531A8 (en) Materials and methods for treatment of allergic diseases
EP1909689A4 (en) Drug-containing implants and methods of use thereof
IL182644A0 (en) Compositions and methods for treatment of protein misfolding and protein aggregation diseases
EP1789047A4 (en) Treatment of diseases using nalmefene and its analgos
ZA200607471B (en) Materials and methods for treatment of allergic disease
ZA200606224B (en) Modified human growth hormone polypeptides and their uses
EP1737481A4 (en) Peptides of il1 beta and tnf alpha and method of treatment using same